Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | CA9 | Q16790 | 1/20 | 0.39 |
| ▸ | MAOA | P21397 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.38 |
| ▸ | MC4R | P32245 | 1/20 | 0.35 |
| ▸ | MC5R | P33032 | 1/20 | 0.35 |
| ▸ | MC3R | P41968 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13046946 | 1.00 | CA1 (0.39) | CA1CA2CA9MAOAL3MBTL1 | |
| SCHEMBL13045626 | 1.00 | CA1 (0.39) | CA1CA2CA9MAOAL3MBTL1 | |
| SCHEMBL13045594 | 0.85 | CA1 (0.36) | CA1CA2CA9MAOAL3MBTL1 | |
| SCHEMBL13045373 | 0.78 | ACHE (0.57) | L3MBTL1 | |
| SCHEMBL13045578 | 0.78 | ACHE (0.57) | L3MBTL1 | |
| SCHEMBL13045719 | 0.78 | ACHE (0.57) | L3MBTL1 | |
| SCHEMBL1703710 | 0.75 | MAOA (0.42) | MAOAL3MBTL1 | |
| SCHEMBL11763516 | 0.75 | CA1 (0.39) | CA1CA2CA9L3MBTL1CYP19A1 | |
| SCHEMBL9775314 | 0.74 | L3MBTL1 (0.52) | L3MBTL1MC4RMC5RMC3R | |
| SCHEMBL1389365 | 0.74 | CA1 (0.39) | CA1CA2CA9MAOACYP19A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120264755-A1 | PYRIDINYL DERIVATIVES AS INHIBITORS OF ENZYME NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE | TopoTarget (DE) | 2012-10-18 | — | — | US | disclosed |
| US-20120264755-A1 | PYRIDINYL DERIVATIVES AS INHIBITORS OF ENZYME NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE | TopoTarget (DE) | 2012-10-18 | — | — | US | disclosed |
| US-20120264755-A1 | PYRIDINYL DERIVATIVES AS INHIBITORS OF ENZYME NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE | TopoTarget (DE) | 2012-10-18 | — | — | US | disclosed |
| WO-2010142735-A1 | PYRIDINYL DERIVATIVES AS INHIBITORS OF ENZYME NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE | TOPOTARGET A/S (DK) | 2010-12-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120264755-A1 | PYRIDINYL DERIVATIVES AS INHIBITORS OF ENZYME NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE | NAMPT, NAPRT, NNT | CA1 4618/4885CA2 3095/4885CA9 3516/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.